U.S. Full Prescribing Information

Medication Guide

BMS Connect

Indication

Visit Patient Site

Component Library

PIVOTAL TRIALS STUDY DESIGN AND RESULTS ❯

This is an h1 tag - 40px/48px

This is an h2 tag - 32px/38.4px

This is an h3 tag - 28px/33.6px

This is an h4 tag - 24px/28.8px

This is an h5 tag - 20px/24px
This is an h6 tag - 16px/19.2px

This is a p tag - 16px/20.8px (#212529)

This ia a Purple Theme (.purple-text) inline style (#be2bbb)

This ia a Light Theme inline style
    color: #FFFFFF

This ia a Dark Theme inline style (#000000)

This ia a Primary Button inline style

This ia a Secondary Button inline style

This ia a Large Text inline style - 24px/31.2px

This ia a Medium Text inline style - 18px/23.4px

This ia a Small text inline style - 14px/18.2px

This ia a Background Container inline style  - (padding:20px; background: transparent linear-gradient(256deg, var(--scope-gradients-light-color-left), var(--scope-gradients-light-color-right)) 0 0 no-repeat padding-box;)

This ia a Warning Box inline style

TEXT LINK INSIDE OF RTE  ❯

THREE REASONS TO CHOOSE SOTYKTU

Simple


ONCE-DAILY
DOSING1‡

Superior efficacy


UP TO 2x THE EFFICACY
VS APREMILAST1*†

Safety profile


THROUGH 4 YEARS
IN CLINICAL TRIALS2,3§

* POETYK PSO-1 (N=664) and POETYK PSO-2 (N=1020) were two, 52-week, multicenter, randomized, double-blind, placebo- and active (apremilast 30 mg twice daily)-controlled, Phase 3 studies to evaluate the safety and efficacy of SOTYKTU (6 mg once daily) in adult patients with moderate-to-severe plaque psoriasis. See additional study design details.1
† Co-primary endpoints: percentage of patients achieving PASI 75 at Week 16 vs placebo and percentage of patients achieving sPGA 0/1 vs placebo at Week 16. The results were achieved for PASI 75 (POETYK PSO-1: 58% vs 13%; POETYK PSO-2: 53% vs 9%) and sPGA 0/1 (POETYK PSO-1: 54% vs 7%; POETYK PSO-2: 50% vs 9%). Statistical significance was achieved for secondary endpoint PASI 90 vs apremilast at Week 24 (POETYK PSO-1: 42% vs 22%; POETYK PSO-2: 32% vs 20%).1
‡ Evaluate patients for active and latent tuberculosis prior to initiating treatment. Update immunizations according to current immunization guidelines. Monitor for laboratory abnormalities. SOTYKTU is not recommended for patients with severe hepatic impairment. Tablets should be taken whole.1
§ Patients had varying lengths of treatment exposure 2,3

SOTYKTU tablet is not actual size. Shown for illustrative purposes only.
PASI=psoriasis area and severity index; PASI 75=≥75% reduction from baseline in PASI; sPGA 0/1=statistic Physician’s Global Assessment, patients achieving clear (0) or almost clear (1) skin.

THREE REASONS TO CHOOSE SOTYKTU

References:
  1. SOTYKTU [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2022.
  2. Lebwohl M, Warren RB, Sofen H, et al. Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase 3 POETYK trials. Br J Dermatol. 2024;190:668-679.
  3. Armstrong AW, Lebwohl M, Warren RB, et al. Deucravacitinib in plaque psoriasis: 4-year safety and efficacy results from the phase 3 POETYK PSO-1, PSO-2 and LTE trials. Oral presentation at: European Academy of Dermatology & Venereology (EADV) Spring Symposium; May 16-18, 2024; St. Julian's, Malta.
IN POETYK PSO-1

~7 out of 10 psoriasis patients achieved PASI 75 with SOTYKTU1,2

PASI 75 RESPONSE RATES, WEEKS 16 AND 24 (NRI)1,2

Data shown is from PSO-1 (NRI)

  • PASI 75 vs apremilast at Week 16 and Week 24 were key secondary endpoints1

VIEW STUDY DESIGN AND
CO-PRIMARY ENDPOINTS ❯

*P<0.0001 vs apremilast.2
BID=twice daily; H2H=head-to-head; NRI=non-responder imputation; PASI=Psoriasis Area and Severity Index; PASI 75=≥75% improvement from baseline in PASI score; QD=once daily; sPGA=static Physician’s Global Assessment. sPGA response defined as PGA score of 0 or 1 with ≥2-point improvement from baseline.

IN POETYK PSO-1

~7 out of 10 psoriasis patients achieved PASI 75 with SOTYKTU1,2

PASI 75 RESPONSE RATES, WEEKS 16 AND 24 (NRI)1,2

*P<0.0001 vs apremilast.2
BID=twice daily; H2H=head-to-head; NRI=non-responder imputation; PASI=Psoriasis Area and Severity Index; PASI 75=≥75% improvement from baseline in PASI score; QD=once daily; sPGA=static Physician’s Global Assessment. sPGA response defined as PGA score of 0 or 1 with ≥2-point improvement from baseline.

ARE YOU READY TO EXPLORE MORE? SELECT A TOPIC BELOW.

SEE POTENTIAL SOTYKTU CANDIDATES ❯

LEARN MORE ABOUT ONCE-DAILY DOSING ❯

RSEE RESOURCES FOR PROFESSIONALS ❯

HELLO

Ready to give SOTYKTU a try?

If you're interested in trying a plaque psoriasis treatment that works differently, it’s time to consider a change.

SOTYKTU easily fits in your daily routine

Take it when and where you choose, once daily, every day—as prescribed by your doctor.

TAKE WHEN AND WHERE YOU WANT

Here are a few ideas that may help make it easier to remember to take your SOTYKTU.

TAKE WHEN AND WHERE YOU WANT

Here are a few ideas that may help make it easier to remember to take your SOTYKTU.

TAKE WHEN AND WHERE YOU WANT

Here are a few ideas that may help make it easier to remember to take your SOTYKTU.

TAKE WHEN AND WHERE YOU WANT

Here are a few ideas that may help make it easier to remember to take your SOTYKTU.

TAKE WHEN AND WHERE YOU WANT

Here are a few ideas that may help make it easier to remember to take your SOTYKTU.

TAKE WHEN AND WHERE YOU WANT

Here are a few ideas that may help make it easier to remember to take your SOTYKTU.

OTHER INFORMATION YOU MAY WANT TO KNO

  • Receive your prescription for SOTYKTU
  • Your dermatologist will let you know if you need to complete any tests before starting SOTYKTU
  • Free trial
    First-time patients may be eligible to receive a free trial of SOTYKTU*
ALT

COMPLETE YOUR ENROLLMENT FORM (AKA SOTYKTU START FORM)

  • Enroll in SOTYKTU 360 SUPPORT with your dermatologist and save our number to your phone.
  • Add our number to your phone—that way you’ll always know when
  • To save our number to your phone, create a new “SOTYKTU 360 SUPPORT” contact on your phone with this number: 1-888-SOTYKTU (768-9588). it’s your
SOTYKTU Coordinator calling.
ALT

COMPLETE YOUR ENROLLMENT FORM (AKA SOTYKTU START FORM)

  • Enroll in SOTYKTU 360 SUPPORT with your dermatologist and save our number to your phone.
  • Add our number to your phone—that way you’ll always know when
  • To save our number to your phone, create a new “SOTYKTU 360 SUPPORT” contact on your phone with this number: 1-888-SOTYKTU (768-9588). it’s your
SOTYKTU Coordinator calling.

OTHER INFORMATION YOU MAY WANT TO KNO

Receive your prescription for SOTYKTU

OTHER INFORMATION YOU MAY WANT TO KNO

Receive your prescription for SOTYKTU

OTHER INFORMATION YOU MAY WANT TO KNO

Receive your prescription for SOTYKTU

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

SOTYKTU is contraindicated in patients with a history of hypersensitivity reaction to deucravacitinib or to any of the excipients in SOTYKTU.

WARNINGS AND PRECAUTIONS

Hypersensitivity: Hypersensitivity reactions such as angioedema have been reported. If a clinically significant hypersensitivity reaction occurs, institute appro‌p‌riate therapy and discontinue SOTYKTU.

Infections: SOTYKTU may increase the risk of infections. Serious infections have been reported in patients with psoriasis who received SOTYKTU. The most common serious infections reported with SOTYKTU included pneumonia and COVID-19. Avoid use of SOTYKTU in patients with an active or serious infection. Consider the risks and benefits of treatment prior to initiating SOTYKTU in patients:

  • with chronic or recurrent infection
  • who have been exposed to tuberculosis
  • with a history of a serious or an opportunistic infection
  • with underlying conditions that may predispose them to infection.

Closely monitor patients for the development of signs and symptoms of infection during and after treatment. A patient who develops a new infection during treatment should undergo prompt and complete diagnostic testing, have appropriate antimicrobial therapy initiated and be closely monitored. Interrupt SOTYKTU if a patient develops a serious infection. Do not resume SOTYKTU until the infection resolves or is adequately treated.

Viral Reactivation

Herpes virus reactivation (e.g., herpes zoster, herpes simplex) was reported in clinical trials with SOTYKTU. Through Week 16, herpes simplex infections were reported in 17 patients (6.8 per 100 patient-years) treated with SOTYKTU, and 1 patient (0.8 per 100 patient-years) treated with placebo. Multidermatomal herpes zoster was reported in an immunocompetent patient. During PSO-1, PSO-2, and the open-label extension trial, the majority of patients who reported events of herpes zoster while receiving SOTYKTU were under 50 years of age. The impact of SOTYKTU on chronic viral hepatitis reactivation is unknown. Consider viral hepatitis screening and monitoring for reactivation in accordance with clinical guidelines before starting and during therapy with SOTYKTU. If signs of reactivation occur, consult a hepatitis specialist. SOTYKTU is not recommended for use in patients with active hepatitis B or hepatitis C.

Tuberculosis (TB): In clinical trials, of 4 patients with latent TB who were treated with SOTYKTU and received appropriate TB prophylaxis, no patients developed active TB (during the mean follow-up of 34 weeks). One patient, who did not have latent TB, developed active TB after receiving 54 weeks of SOTYKTU. Evaluate patients for latent and active TB infection prior to initiating treatment with SOTYKTU. Do not administer SOTYKTU to patients with active TB. Initiate treatment of latent TB prior to administering SOTYKTU. Consider anti-TB therapy prior to initiation of SOTYKTU in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Monitor patients for signs and symptoms of active TB during treatment.

Malignancy including Lymphomas: Malignancies, including lymphomas, were observed in clinical trials with SOTYKTU. Consider the benefits and risks for the individual patient prior to initiating or continuing therapy with SOTYKTU, particularly in patients with a known malignancy (other than a successfully treated non-melanoma skin cancer) and patients who develop a malignancy when on treatment with SOTYKTU.

Rhabdomyolysis and Elevated CPK: Treatment with SOTYKTU was associated with an increased incidence of asymptomatic creatine phosphokinase (CPK) elevation and rhabdomyolysis compared to placebo. Discontinue SOTYKTU if markedly elevated CPK levels occur or myopathy is diagnosed or suspected. Instruct patients to promptly report unexplained muscle pain, tenderness or weakness, particularly if accompanied by malaise or fever.

Laboratory Abnormalities: Treatment with SOTYKTU was associated with increases in triglyceride levels. Periodically evaluate serum triglycerides according to clinical guidelines during treatment. SOTYKTU treatment was associated with an increase in the incidence of liver enzyme elevation compared to placebo. Evaluate liver enzymes at baseline and thereafter in patients with known or suspected liver disease according to routine management. If treatment-related increases in liver enzymes occur and drug-induced liver injury is suspected, interrupt SOTYKTU until a diagnosis of liver injury is excluded.

Immunizations: Prior to initiating therapy with SOTYKTU, consider completion of all age-appropriate immunizations according to current immunization guidelines including prophylactic herpes zoster vaccination. Avoid use of live vaccines in patients treated with SOTYKTU. The response to live or non-live vaccines has not been evaluated.

Potential Risks Related to JAK Inhibition: It is not known whether tyrosine kinase 2 (TYK2) inhibition may be associated with the observed or potential adverse reactions of Janus Kinase (JAK) inhibition. In a large, randomized, postmarketing safety trial of a JAK inhibitor in rheumatoid arthritis (RA), patients 50 years of age and older with at least one cardiovascular risk factor, higher rates of all-cause mortality, including sudden cardiovascular death, major adverse cardiovascular events, overall thrombosis, deep venous thrombosis, pulmonary embolism, and malignancies (excluding non-melanoma skin cancer) were observed in patients treated with the JAK inhibitor compared to those treated with TNF blockers. SOTYKTU is not approved for use in RA.

ADVERSE REACTIONS

Most common adverse reactions (≥1% of patients on SOTYKTU and more frequently than with placebo) include upper respiratory infections, blood creatine phosphokinase increased, herpes simplex, mouth ulcers, folliculitis and acne.

SPECIFIC POPULATIONS

Pregnancy: Available data from case reports on SOTYKTU use during pregnancy are insufficient to evaluate a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Report pregnancies to the Bristol-Myers Squibb Company’s Adverse Event reporting line at 1-800-721-5072.

Lactation: There are no data on the presence of SOTYKTU in human milk, the effects on the breastfed infant, or the effects on milk production. SOTYKTU is present in rat milk. When a drug is present in animal milk, it is likely that the drug will be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for SOTYKTU and any potential adverse effects on the breastfed infant from SOTYKTU or from the underlying maternal condition.

Hepatic Impairment: SOTYKTU is not recommended for use in patients with severe hepatic impairment.

SOTYKTU is available in 6 mg tablets.

INDICATION

SOTYKTU® (deucravacitinib) is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

Limitations of Use:

SOTYKTU is not recommended for use in combination with other potent immunosuppressants.

Please see U.S. Full Prescribing Information, including Medication Guide, for SOTYKTU.

Bristol Myers Squibb® Logo

SOTYKTU, SOTYKTU 360 SUPPORT, and SOTYKTU logo are trademarks of Bristol-Myers Squibb Company.
This site is intended for U.S. Healthcare Professionals only.
Otezla is a registered trademark of Amgen Inc.
© 2024 Bristol-Myers Squibb Company.
1787-US-2400641 11/24

Legal Notice   |   Privacy Policy   |   Your Privacy Choices Privacy Link   |   Sitemap